Standard BioTools financials
$0.7133−1.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $85.3M | $91.0M | $106.3M | $97.9M |
| Gross profit | $42.5M | $44.9M | $50.5M | $37.1M |
| Gross margin | 49.9% | 49.3% | 47.4% | 37.8% |
| Operating income | -$110.2M | -$127.5M | -$76.6M | -$116.2M |
| Net income | -$74.9M | -$184.9M | -$74.7M | -$190.1M |
| Net margin | −87.8% | −203.2% | −70.2% | −194.1% |
| Diluted EPS | $-0.20 | $-0.52 | $-0.94 | $-2.43 |
| EBITDA | -$82.3M | -$70.1M | -$47.9M | -$91.4M |
| Operating cash flow | -$74.3M | -$143.5M | -$43.3M | -$89.4M |
| Free cash flow | -$82.6M | -$151.8M | -$46.1M | -$93.2M |
| Diluted shares | 381.6M | 353.2M | 79.2M | 78.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $120.9M | $166.7M | $51.7M | $81.3M |
| Short-term investments | $66.7M | $126.1M | $63.2M | $84.5M |
| Total debt | $299.0K | $299.0K | $63.5M | $64.9M |
| Total assets | $567.8M | $612.3M | $323.1M | $390.3M |
| Total liabilities | $143.5M | $140.6M | $159.9M | $160.5M |
| Shareholders' equity | $424.3M | $471.7M | -$148.1M | -$81.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology